Key Highlights
- Christopher Gleason appointed as President and CEO of Moximed
- MISHA® Knee System to expand access for knee osteoarthritis patients in the U.S.
- Gleason brings extensive experience in commercializing disruptive medical technologies
- Gleason aims to advance patient care with Moximed’s talented team
Source: Business Wire
Notable Quotes
- “It is an honor to join Moximed as we expand access of the MISHA® Knee System to the many knee OA patients in the U.S. who may benefit.” – Christopher Gleason, President and CEO at Moximed
- “We’re seeing tremendous clinical results from commercial use of the MISHA Knee System, and it’s the perfect time for Chris to broaden our commercial reach and enable greater product access for the benefit of patients.” – Anton Clifford, Ph.D., Co-Founder and CTO at Moximed
- “Moximed has a transformational, breakthrough product for the treatment of medial compartment knee osteoarthritis, and it is exciting to see Chris step in to lead this talented and resilient team towards the establishment of the MISHA Knee System as a new standard of care.” – Josh Makower, M.D., Co-Founder and Chairman of the Board of Directors at Moximed
SoHC's Take
Christopher Gleason’s appointment as President and CEO of Moximed marks a pivotal moment for the company and the broader field of knee osteoarthritis treatment. His extensive background in successfully commercializing medical technologies positions Moximed to significantly enhance the reach and impact of its innovative MISHA® Knee System. This system offers a crucial alternative for patients seeking to manage knee OA without resorting to total knee replacement, thereby preserving their quality of life and daily function. With Gleason at the helm, Moximed is well-poised to revolutionize the standard of care for knee OA sufferers in the U.S., potentially transforming patient outcomes and the orthopedic landscape.
